Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

FATE THERAPEUTICS INC Director's Dealing 2014

May 5, 2014

34091_dirs_2014-05-05_518b68e4-d1a7-4be9-a1fc-9ee8f7b657c3.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: FATE THERAPEUTICS INC (FATE)
CIK: 0001434316
Period of Report: 2014-05-01

Reporting Person: Flynn Peter D (See remarks)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2014-05-01 Common Stock M 6925 $1.63 Acquired 13656 Direct
2014-05-01 Common Stock M 1100 $1.63 Acquired 14756 Direct
2014-05-01 Common Stock M 422 $1.37 Acquired 15178 Direct
2014-05-01 Common Stock S 9793 $7.0662 Disposed 5385 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2014-05-01 Stock Option (right to buy) $1.63 M 6925 Disposed 2022-02-08 Common Stock (6925) Direct
2014-05-01 Stock Option (right to buy) $1.63 M 1100 Disposed 2022-02-08 Common Stock (1100) Direct
2014-05-01 Stock Option (right to buy) $1.37 M 422 Disposed 2022-07-23 Common Stock (422) Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 19, 2013.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.00 to $7.19, inclusive.

F3: The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.

F4: The shares subject to this option shall vest and become exercisable at the rate of 1/4th of the shares on May 30, 2012 and 1/48th of the shares each month thereafter such that this option is fully exercisable on May 30, 2015. This option is subject to accelerated vesting upon a change of control of the Issuer and in the event of termination of employment under certain circumstances following a change of control of the Issuer.

F5: Not applicable.

F6: The shares subject to this option shall vest and become exercisable in 24 equal monthly installments beginning on the date one month after the completion of the Issuer's initial public offering. This option is subject to accelerated vesting upon a change of control of the Issuer after the completion of the Issuer's initial public offering.

F7: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments beginning on August 3, 2012 such that this option is fully exercisable on July 3, 2016. This option is subject to accelerated vesting upon a change of control of the Issuer and in the event of termination of employment under certain circumstances following a change of control of the Issuer.